- Home
- CYCN vs SLXN Comparison
CYCN vs SLXN Comparison
Compare CYCN & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- SLXN
- Stock Information
- Founded
- CYCN 2018
- SLXN 2008
- Country
- CYCN United States
- SLXN Israel
- Employees
- CYCN N/A
- SLXN N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- CYCN Health Care
- SLXN
- Exchange
- CYCN Nasdaq
- SLXN NYSE
- Market Cap
- CYCN 6.5M
- SLXN 7.3M
- IPO Year
- CYCN N/A
- SLXN N/A
- Fundamental
- Price
- CYCN $3.62
- SLXN $0.80
- Analyst Decision
- CYCN
- SLXN Strong Buy
- Analyst Count
- CYCN 0
- SLXN 1
- Target Price
- CYCN N/A
- SLXN $5.00
- AVG Volume (30 Days)
- CYCN 30.1K
- SLXN 707.7K
- Earning Date
- CYCN 08-06-2025
- SLXN 08-21-2025
- Dividend Yield
- CYCN N/A
- SLXN N/A
- EPS Growth
- CYCN N/A
- SLXN N/A
- EPS
- CYCN N/A
- SLXN N/A
- Revenue
- CYCN $2,081,000.00
- SLXN N/A
- Revenue This Year
- CYCN N/A
- SLXN N/A
- Revenue Next Year
- CYCN N/A
- SLXN N/A
- P/E Ratio
- CYCN N/A
- SLXN N/A
- Revenue Growth
- CYCN N/A
- SLXN N/A
- 52 Week Low
- CYCN $1.27
- SLXN $0.58
- 52 Week High
- CYCN $9.47
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- CYCN 63.94
- SLXN N/A
- Support Level
- CYCN $2.95
- SLXN N/A
- Resistance Level
- CYCN $3.73
- SLXN N/A
- Average True Range (ATR)
- CYCN 0.33
- SLXN 0.00
- MACD
- CYCN 0.06
- SLXN 0.00
- Stochastic Oscillator
- CYCN 89.22
- SLXN 0.00
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.